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Purpose: To assess safety and efficacy of EGP-437 (dexamethasone phosphate 40 mg/mL 
[DP]) in dry eye patients.
Methods: The study employed a prospective, single-center, double-masked design utilizing a 
Controlled Adverse Environment (CAE). Patients (n = 103) with confirmed signs and symptoms 
of dry eye syndrome were randomized into 1 of 3 iontophoresis treatment groups: 7.5 mA-
min at 2.5 mA (DP 7.5, n = 41); 10.5 mA-min at 3.5 mA (DP 10.5, n = 37); or 10.5 mA-min 
at 3.5 mA (placebo, n = 25). Three CAE visits and 4 follow-up visits occurred over 3 weeks. 
Patients meeting enrollment criteria received iontophoresis in both eyes after the second CAE 
exposure (visit 3) and before the third CAE exposure (visit 5). Primary efficacy endpoints were 
corneal staining and ocular discomfort. Secondary endpoints included tear film break-up time, 
ocular protection index (OPI), and symptomatology.
Results: The DP 7.5 and DP 10.5 treatment groups showed statistically significant improve-
ments in signs and symptoms of dry eye at various time points; however, the primary endpoints 
were not achieved. The DP 7.5 treatment group exhibited statistically significant improvements 
in corneal staining (when comparing the differences between study entry and exit, 3 weeks, 
P = 0.039), OPI (immediately following the second treatment, P = 0.048) and ocular discom-
fort at follow-up visits (a week after the first treatment, P = 0.032; 24 hours after the second 
treatment, P = 0.0032). Treatment-emergent adverse events (AEs) were experienced by 87% 
of patients and were consistent across all treatment groups. Most AEs were mild and no severe 
AEs were observed.
Conclusion: Ocular iontophoresis of EGP-437 demonstrated statistically and clinically signifi-
cant improvements in signs and symptoms of dry eye syndrome within a CAE model.
Keywords: iontophoresis, dry eye, Controlled Adverse Environment (CAE), ocular protection 
index (OPI)
Introduction
Dry eye syndrome is a “disorder of tear film deficiency, which leads to damage to 
the interpalpebral ocular surface and symptoms of ocular discomfort”.1 Prevalence 
estimates of the disease range from 5% to 35% of individuals worldwide over age 
50 years, with an estimated 5 to 6 million Americans reporting experiences of signifi-
cant dry eye symptomatology.2
Patients with milder forms of dry eye often achieve transient, symptomatic relief 
from using over-the-counter topical ophthalmic formulations. These products can 
replenish the tear film and normalize the elevated tear osmolarity often associated 
with dry eye, but they do not treat the underlying cause of the disease.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Chronic forms of dry eye require more intensive, 
  longer-lasting therapeutic interventions. US Food and Drug 
Administration (FDA)-approved treatments include biode-
gradable inserts that act as prolonged-release ocular surface 
lubricants, and punctal plugs, which can slow tear film drain-
age. However, punctal plug users may experience spontaneous 
extrusion or migration of plugs, as well as a counterproductive 
reduction in tear secretion due to reduced drainage.3
Restasis® (0.05% topical suspension, Allergan Inc, 
Irvine, CA) is the only FDA-approved drug for dry eye; spe-
cifically, it is indicated for patients with ocular inflammation 
due to keratoconjunctivitis sicca.4 While the exact mechanism 
of action is unknown, it is thought to act by stimulating tear 
  production.4 Restasis has proven to be an effective treatment 
for only 15% of patients treated;4,5 therefore, the need for effec-
tive therapies to treat dry eye disease remains substantial.
The lack of available drug treatments for dry eye disease 
may be related to the multifaceted nature of the disease, both 
in terms of the causes and manifestations. These factors com-
plicate therapeutic target identification.6 Growing scientific 
evidence obtained from studying a broad range of dry eye 
patients suggests that inflammation is either an underlying 
component or a primary cause of the tear film disruption; 
therefore, anti-inflammatory therapy is likely to be efficacious 
in a diverse patient population.7–9
Topical corticosteroids are used off-label to reduce signs 
and symptoms of dry eye.10 These drugs suppress inflam-
mation through multiple pathways.11 While corticosteroid 
eyedrops are widely used to treat dry eye,12 their low ocular 
bioavailability (estimated to be 1% to 10%) may limit their 
effectiveness. This may be related to the eye’s natural pro-
tective barriers; for example, the tear film may dilute the 
formulation and clear it rapidly through normal drainage 
channels before the drug can be absorbed (ie, a short resi-
dence time).13,14 In addition, chronic uninterrupted steroid 
use may lead to possible side effects, including cataract 
formation and elevation of intraocular pressure (IOP).15 The 
use of pulsatile dosing for corticosteroids may help minimize 
the safety related concerns; however, this approach does not 
address the limited ocular bioavailability. Therefore, alter-
native corticosteroid dosing techniques that enhance drug 
bioavailability in the eye, such as iontophoresis, may be a 
viable therapeutic option.
In ocular iontophoresis, a small applied current forms 
an electrical field at the ocular surface, which crosses into 
anterior and posterior segments. Under the influence of this 
field, the mobility of charged particles becomes enhanced. 
Placing drug molecules into the field may lead to   substantially 
higher ocular drug concentrations than achieved with 
  eyedrops. In 1943, the first ocular iontophoretic application 
was reported.16 Later, Maurice and colleagues advanced the 
use of iontophoresis as a means to enhance drug delivery 
to ocular tissues.17,18 More recently, Lam et al19 showed that 
iontophoresis-delivered vitreal dexamethasone was 3500- and 
700-fold higher than either topical instillation or subcon-
junctival injection, respectively. This enhanced delivery can 
also prolong the duration of drug action, as demonstrated 
in a study of iodide iontophoresis in which extended drug 
exposure was demonstrated compared to topical iodide 
application without current.20
In order to develop an optimal drug product for use with 
ocular iontophoresis, physicochemical properties of candidate 
compounds must be considered, and special attention must be 
paid to formulation optimization, including drug substance 
concentration, excipient content, and osmolality.21
Dexamethasone and dexamethasone phosphate have 
demonstrated long-term safety and efficacy in humans, 
and have well-characterized safety and efficacy profiles 
for ophthalmic indications. Dexamethasone phosphate 
is a prodrug of dexamethasone, and readily converts to 
dexamethasone in vivo. Dexamethasone lacks a charged 
group and has limited aqueous solubility (0.1 mg/mL).22 
In contrast, dexamethasone phosphate possesses 2 acidic 
protons that allow the production of highly water soluble 
formulations of a charged species within the pH range 
of 5.5 to 7.4; therefore, it is a suitable candidate for 
iontophoresis.19
A novel ocular iontophoresis platform, the EyeGate® 
II system (Eyegate Pharmaceuticals, Inc, Waltham, MA), 
has been designed to deliver drugs through the conjunctiva 
and sclera.23 Preclinical studies guided the development of 
a 40 mg/mL dexamethasone phosphate solution (EGP-437, 
Eyegate Pharmaceuticals, Inc) for specific use with the 
Eyegate® II device. In rabbits, iontophoresis of EGP-437 
delivered significantly higher (∼100+ fold) aqueous humor 
drug concentration levels than that achieved with either 
topical or intravenous administration.23 Furthermore, in a 
rabbit model of dry eye, a single iontophoresis treatment 
of 40 mg/mL dexamethasone phosphate solution led to 
full recovery within 2 days, as measured by corneal fluo-
rescein staining and tear volume, using Schirmer’s test; 
these effects were sustained through the 10-day duration 
of the study.24
The clinical study described herein explored the safety 
and efficacy of ocular iontophoresis of EGP-437 (40 mg/mL 
dexamethasone phosphate solution) in dry eye patients.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Methods
This single-center, double-masked, randomized, placebo-
controlled phase II trial evaluated ocular iontophoresis 
of EGP-437 in patients with moderate to severe dry eye 
  syndrome. Patients were recruited from an existing patient 
database or by using an Institutional Review Board–approved 
advertisement.   General guidelines for dry eye diagnosis fol-
lowed standards set at the international dry eye workshop.1 
Enrollment was open to patients at least 12 years of age, who 
had a medical history of ongoing moderate to severe dry 
eye, reported the use or desire to use artificial tears in both 
eyes, and demonstrated best corrected visual acuities in both 
eyes of 0.5 logMAR or better on the ETDRS chart.
Patients were excluded from study enrollment if they 
had known contraindications, allergy, or sensitivity to the 
test articles. They were also excluded if they were currently 
pregnant, nursing, or planning a pregnancy; had any medical 
conditions that in the investigator’s opinion could impede 
the iontophoresis application (eg, pacemakers) or study 
parameters, or that could put the patient’s health at sub-
stantial risk. Pregnancy tests were administered to females 
of childbearing potential at visit 1, and those patients were 
asked to use an acceptable contraceptive method for the 
duration of the study. Follow-up pregnancy tests were admin-
istered at visit 7. Patients who had used certain medications 
(other investigative drugs, ocular drying medications, ocular 
steroids, Restasis®) within the previous 4 weeks were also 
excluded. Contact lens wearers and those who had under-
gone LASIK surgery within the previous 12 months were 
also excluded.
The study used the Controlled Adverse Environment 
(CAE) model25 developed by Ora, Inc, Andover, MA to 
assess the signs and symptoms of dry eye. This model is 
designed to emulate extreme environmental conditions 
(eg, low humidity, high temperature, visual tasking) that 
contribute to drying of the ocular surface. The CAE system 
exacerbates the signs and symptoms of dry eye in a repro-
ducible reversible manner,25–28 and correlates with murine 
models of dry eye disease.29
study design
This exploratory study was designed to evaluate effects 
among different clinical scenarios: treatment, the effects of 
iontophoresis-delivered dexamethasone phosphate following 
CAE-induced dry eye signs and symptoms; prevention, the 
effects of iontophoresis-delivered dexamethasone phosphate 
prior to CAE exposure; recovery, the effects of iontophoresis-
delivered dexamethasone phosphate on recovery toward 
baseline at follow-up visits (24 hours and 7 days after CAE); 
and “environmental  ” (periods of time not directly influenced 
by the CAE), the ability of iontophoresis-delivered dexam-
ethasone phosphate to improve dry eye signs and symptoms 
over the entire 3-week study period.
The study included 7 visits over 3 weeks: 3 visits 
(visits 1, 3, and 5), in which patients were exposed to the 
CAE for 90 minutes, and 4 follow-up visits (visits 2, 4, 6, 
and 7) (Figure 1). At visit 1 (day -7 ± 2), patients provided 
written informed consent prior to any study procedures, 
and clinical staff collected medical and medication history 
data. Prior to and after CAE exposure, patients completed 
symptom questionnaires, had their blink rates captured 
using an infrared camera mounted on a headset, underwent 
ophthalmic exams including slit lamp biomicroscopy, and 
conjunctival redness grading based on the Ora 5-point scale 
(0 = none to 4 = severe). Ocular surface staining using the 
Ora28 regions was assessed on a 5-point scale (0 = none to 
4 = confluent). Fluorescein and lissamine green stains were 
used – fluorescein to assess the cornea and lissamine green 
to evaluate the conjunctiva. Tear film break-up time (TFBUT) 
data were also captured. Ocular Protection Index (OPI) values 
were calculated by dividing the TFBUT by the mean inter-
blink interval (derived from blink rate).30 A complete enumera-
tion of procedures and assessments is provided in Table 1.
During CAE exposure, patients reported ocular discom-
fort scores on a 5-point scale (0 = none to 4 = severe) every 
5 minutes.28 After completing CAE exposure, investigators 
assessed corneal sensitivity using a Cochet-Bonnet aesthe-
siometer. In order to ensure that the study sample included 
patients with significant disease and a dynamic range of 
relevant signs and symptoms, patients were screened for 
demonstrated baseline signs and symptoms of dry eye prior 
to CAE exposure (corneal staining .1 and presence of 
conjunctival redness) and a CAE-induced response such as 
increases in ocular discomfort scores and fluorescein staining 
in at least 1 eye. This value for corneal staining corresponds 
to occasional fluorescein deposition. Qualifying patients 
received a diary in which to record their symptoms 3 times 
daily for the duration of the study.
Visits 1 and 3 procedures were similar. Patients who 
continued to meet qualification criteria after visit 3 (day 0) 
CAE exposure were randomized into the study according to 
a predefined randomization code generated by an indepen-
dent biostatistician, and received ocular iontophoresis of 
either: dexamethasone phosphate 40 mg/mL, 7.5 mA-min 
at 2.5 mA (DP 7.5); dexamethasone phosphate 40 mg/mL, 
10.5 mA-min at 3.5 mA (DP 10.5); or sodium citrate   buffer Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Screen
and
qualify
Randomize
and
Dose 1 Dose 2
Treatment
V1 V2 V3 V4 V5 V6 V7
81 52 2 1
Prevention
3 week
“Environmental”
V2, V4, and V6 occur 24 hours after
visits V1, V3 and V5 respectively
CAE
24 hr recovery & evaluation
5–6 day recovery
Figure 1 study visit schedule. Diagram represents the overall study timeline, delineating the temporal relationship between screening visits, Controlled Adverse environment 
(CAe) and drug dosing sessions, and the recovery period.
solution 100 mM, 10.5 mA-min at 3.5 mA (placebo). 
An unmasked technician identified the proper treatment 
group according to the randomization scheme, and then 
loaded the appropriate drug product from a standard vial 
into the foam reservoir of the ocular applicator. At least 
1 hour after qualifying patients exited the CAE, patients were 
treated. Prior to placing the ocular iontophoresis applicator on 
the eye, the masked investigator instilled a topical anesthetic. 
The unmasked technician programmed the appropriate dose 
into the iontophoresis generator, concealed the device from 
the investigator, and then initiated   treatment. The unmasked 
technician performed no other study procedures. The treat-
ment process was then repeated for the other eye (Figure 2). 
Visit 5 procedures were the same as those at visit 3, but the 
visit 5 iontophoresis treatments were performed prior to 
CAE exposure.
At the follow-up visits (visit 2 [day -7 + 24 ± 3 hours], 
visit 4 [day 0 + 24 ± 3 hours], visit 6 [day 7 + 24 ± 3 hours], 
and visit 7 [day 14 ± 2]), medical and medication histories 
were updated, and patients underwent all visit 1 study pro-
cedures except for CAE exposure and post-CAE exams and 
questionnaires. Patients were asked to complete an additional 
ocular discomfort assessment at visits 4, 5, 6, and 7, as well as 
an overall global rating for the treatments at visit 7. Adverse 
events (AEs) that were elicited from patients or observed by 
investigators for the duration of the study were recorded and 
assessed for severity and possible cause.
statistical methods
The sample size determination of 30 in each DP group and 
20 in the placebo group was based on a family-wise type 
I error of 0.05. Assuming common standard deviation of 
1.2 units for corneal fluorescein staining typical of CAE stud-
ies, the sample size determination had approximately 80% 
power to identify true mean difference in corneal staining of 
1.0 unit. Likewise, assuming common standard deviations of 
1.0 unit for ocular discomfort in the CAE, the sample size 
described above was estimated to have 90% power to identify 
true 1.0-unit mean difference in ocular discomfort.
Every randomized patient, for whom there was any 
evidence that study medication was used, and for whom 
follow-up safety data were available, was considered evalu-
able for safety purposes, comprising the safety population. 
The intent-to-treat (ITT) population included all randomized 
patients. The per-protocol (PP) population excluded ITT 
patients (prior to locking the database) with any major pro-
tocol deviations that could impact the efficacy analysis.
Primary efficacy analyses (DP dose groups compared 
with placebo, corneal fluorescein staining post-CAE at 
visit 5 and ocular discomfort during CAE exposure at 
visit 5) were performed on the ITT population using the 
worst eligible (WE) eye. The technique of last observation 
carried forward (LOCF) was used in cases of missing 
efficacy data variables. Corneal fluorescein staining results 
were analyzed using a t-test and a Wilcoxon rank sum Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
637
Ocular iontophoresis of dexamethasone phosphate in dry eye patients
T
a
b
l
e
 
1
 
P
r
o
c
e
d
u
r
e
s
 
a
n
d
 
a
s
s
e
s
s
m
e
n
t
s
 
s
u
m
m
a
r
y
V
i
s
i
t
 
#
1
2
3
4
5
6
7
D
a
y
1
-
7
 
±
 
2
 
d
a
y
s
-
6
 
±
 
3
 
h
o
u
r
s
0
1
 
±
 
3
 
h
o
u
r
s
7
 
±
 
2
 
d
a
y
s
8
 
±
 
3
 
h
o
u
r
s
1
4
 
±
 
2
 
d
a
y
s
P
r
o
c
e
d
u
r
e
P
r
e
 
C
A
E
P
o
s
t
 
C
A
E
P
r
e
 
C
A
E
P
o
s
t
 
C
A
E
P
r
e
 
C
A
E
P
o
s
t
 
C
A
E
i
n
f
o
r
m
e
d
 
c
o
n
s
e
n
t
X
M
e
d
i
c
a
l
 
h
i
s
t
o
r
y
X
D
e
m
o
g
r
a
p
h
i
c
 
d
a
t
a
X
M
e
d
i
c
a
l
 
h
i
s
t
o
r
y
 
u
p
d
a
t
e
X
X
X
X
X
X
P
r
e
g
n
a
n
c
y
 
t
e
s
t
X
2
X
2
O
c
u
l
a
r
 
d
i
s
c
o
m
f
o
r
t
 
–
 
O
r
A
X
X
X
X
X
X
X
X
X
X
4
-
s
y
m
p
t
o
m
 
q
u
e
s
t
i
o
n
n
a
i
r
e
X
X
X
X
X
X
X
X
X
X
O
s
D
i
 
q
u
e
s
t
i
o
n
n
a
i
r
e
X
X
X
X
X
X
X
V
A
s
 
–
 
t
e
s
t
 
a
r
t
i
c
l
e
X
X
V
A
s
 
–
 
o
c
u
l
a
r
 
d
i
s
c
o
m
f
o
r
t
X
X
X
X
X
g
l
o
b
a
l
 
r
a
t
i
n
g
X
V
i
s
u
a
l
 
a
c
u
i
t
y
 
(
e
T
D
r
s
)
X
X
X
X
X
X
X
B
l
i
n
k
 
r
a
t
e
X
X
X
X
X
X
X
X
X
X
s
l
i
t
-
l
a
m
p
 
b
i
o
m
i
c
r
o
s
c
o
p
y
X
X
X
X
X
X
X
X
X
X
C
o
n
j
u
n
c
t
i
v
a
l
 
r
e
d
n
e
s
s
X
X
X
X
X
X
X
X
X
X
T
F
B
U
T
X
X
X
X
X
X
X
X
X
X
O
P
i
X
X
X
X
X
X
X
X
X
X
F
l
u
o
r
e
s
c
e
i
n
 
s
t
a
i
n
i
n
g
X
X
X
X
X
X
X
X
X
X
L
i
s
s
a
m
i
n
e
 
g
r
e
e
n
 
s
t
a
i
n
i
n
g
X
X
X
X
X
X
X
X
X
X
C
A
e
 
e
x
p
o
s
u
r
e
X
X
X
C
A
e
 
d
i
s
c
o
m
f
o
r
t
X
3
X
3
X
3
C
o
r
n
e
a
l
 
s
e
n
s
i
t
i
v
i
t
y
X
X
X
r
a
n
d
o
m
i
z
a
t
i
o
n
X
A
n
e
s
t
h
e
t
i
c
 
i
n
s
t
i
l
l
a
t
i
o
n
X
X
T
e
s
t
 
a
r
t
i
c
l
e
 
t
r
e
a
t
m
e
n
t
X
X
D
i
a
r
y
 
d
i
s
p
e
n
s
a
t
i
o
n
X
X
X
X
X
X
D
i
a
r
y
 
c
o
l
l
e
c
t
i
o
n
X
X
X
X
X
X
A
d
v
e
r
s
e
 
e
v
e
n
t
 
q
u
e
r
y
X
X
X
X
X
X
e
x
i
t
 
p
a
t
i
e
n
t
 
f
r
o
m
 
s
t
u
d
y
X
N
o
t
e
s
:
 
D
a
y
1
 
f
o
r
 
v
i
s
i
t
s
 
2
,
 
4
,
 
a
n
d
 
6
,
 
v
i
s
i
t
s
 
o
c
c
u
r
 
2
4
 
h
o
u
r
s
 
f
o
l
l
o
w
i
n
g
 
p
r
e
v
i
o
u
s
 
v
i
s
i
t
,
 
±
3
 
h
o
u
r
s
;
 
X
2
 
=
 
f
o
r
 
f
e
m
a
l
e
s
 
o
f
 
c
h
i
l
d
b
e
a
r
i
n
g
 
p
o
t
e
n
t
i
a
l
,
 
X
3
 
=
 
p
r
o
c
e
d
u
r
e
 
c
o
n
d
u
c
t
e
d
 
a
t
 
t
i
m
e
 
0
 
a
n
d
 
e
v
e
r
y
 
5
 
m
i
n
u
t
e
s
 
t
h
e
r
e
a
f
t
e
r
 
d
u
r
i
n
g
 
t
h
e
 
9
0
-
m
i
n
u
t
e
 
C
A
e
 
e
x
p
o
s
u
r
e
.
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
C
A
E
,
 
C
o
n
t
r
o
l
l
e
d
 
A
d
v
e
r
s
e
 
E
n
v
i
r
o
n
m
e
n
t
;
 
O
P
I
,
 
O
c
u
l
a
r
 
P
r
o
t
e
c
t
i
o
n
 
I
n
d
e
x
;
 
O
S
D
I
,
 
O
c
u
l
a
r
 
S
u
r
f
a
c
e
 
D
i
s
e
a
s
e
 
I
n
d
e
x
;
 
T
F
B
U
T
,
 
t
e
a
r
 
fi
l
m
 
b
r
e
a
k
-
u
p
 
t
i
m
e
;
 
V
A
S
,
 
v
i
s
u
a
l
 
a
n
a
l
o
g
 
s
c
a
l
e
.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
638
Patane et al
test during the treatment period (pre- and post-CAE), and 
an analysis of covariance (ANCOVA) model was used to 
calculate least square means (LS means) and P values. 
Ocular discomfort data during CAE exposure were used to 
calculate the area under the curve (AUC) for each eye using 
the trapezoidal rule.31 Statistical hypothesis testing was pri-
marily performed for the worse eye by using a linear model 
(ANOVA) to assess treatment group differences with AUC 
as the response.   Secondarily, statistical hypothesis testing 
was also performed by an ANCOVA model with time, treat-
ment effects, and the interactions carried out across all time 
points accounting for repeated measures per patient.
For secondary efficacy variables, all pair-wise compari-
sons for each quantitative variable were performed using 
both a t-test and a Wilcoxon rank sum test during the treat-
ment period; an ANCOVA model was used to calculate LS 
Means and P values. A Chi-square test, or Fisher’s exact 
test in the case of expected counts ,5, was used for the 
discrete or binary variables without stratification for all 
pair-wise comparisons. Additional analyses for the sec-
ondary efficacy variables were performed using the same 
statistical models, on the following analysis populations: 
ITT-observed data only (ODO)-WE, ITT-ODO-all eligible 
eyes (AEE), PP population-WE, and PP population-AEE. 
All treatment effects were assessed at a significance level 
of 5%. All safety analyses were performed on the safety 
population. AEs were coded using the MedDRA dictionary 
(version 11.0) and classified by system organ class and pre-
ferred term. A series of post-hoc analyses were carried out 
to explore areas where the primary or secondary endpoints 
demonstrated statistically significant findings or indicated 
trends of interest. For consistency, the secondary efficacy 
and post-hoc findings are discussed for the PP-WE analysis 
population.
Results
Demographics
A total of 105 patients (mean age: 53 years, range 18 to 84; 
32% male; 89% Caucasian) were randomized into three 
treatment groups comprising the ITT population. There were 
no significant differences between groups for age or male/
female ratios. One hundred and three patients received study 
treatments via iontophoresis, comprising the safety popula-
tion. Of the 105 randomized patients, 2 withdrew from the 
study prior to receiving treatment. The PP population con-
sisted of the 83 patients who completed the study with no 
major protocol violations. The patient disposition is shown 
in Figure 3.   Fourteen patients did not complete the study 
for various reasons, including two that received the wrong 
treatment. No patient was discontinued from the study as 
a result of a protocol deviation; however, six patients were 
excluded from the PP population for the following reasons: 
completed visit 5 out-of-window (n = 4), took exclusionary 
medication (n = 1), and received the wrong treatment via 
technician error (n = 1). Patients who received the wrong 
treatment were included in the ITT population as treated.
signs
There were no statistically significant differences among 
the treatment groups for the primary sign endpoint of 
corneal staining post-CAE at visit 5 in the ITT-LOCF-WE 
analysis population. However, the DP 7.5 treatment group 
demonstrated less lissamine green corneal staining than the 
placebo group pre- to post-CAE at visit 5 in the superior 
region (PP-WE; P = 0.017, t-test; P = 0.039, Wilcoxon). 
Statistically significant improvements in TFBUT were 
observed for DP 7.5 treatment relative to placebo at visit 5 
pre- and post-CAE (PP-WE; P = 0.034, 0.049, respectively, 
t-test) and at visit 7 (PP-WE; P = 0.042, t-test). Significant 
improvements in OPI were observed for DP 7.5 treatment 
relative to placebo at visit 5 post-CAE (PP-WE; P = 0.048, 
Chi-square test). While the DP 10.5 treatment group values 
displayed improvements compared with placebo for all of 
these criteria, none reached the level of statistical significance 
(P , 0.05). A listing of statistically significant findings is 
shown in Table 2.
At visit 7, differences between the DP 7.5 treatment and 
placebo groups were documented, including the TFBUT 
as described above and a trend toward improved corneal 
fluorescein staining (inferior region of the Ora scale in the 
ITT-LOCF-WE, P = 0.086, two-sample t-test and P = 0.092, 
Wilcoxon). When comparing endpoints across the entire 
study’s duration (between visit 1 baseline and visit 7   
Figure 2 Ocular iontophoresis application. The photo shows the iontophoretic 
applicator placement on the eye.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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study exit), a statistically significant decrease in fluorescein 
staining in the inferior region of the Ora scale was revealed 
for the DP 7.5 treatment group over placebo (0.51, P = 0.038, 
Wilcoxon, Figure 4).
symptoms
The differences in mean ocular discomfort scores between 
both DP groups and placebo during CAE exposure at visit 5, 
the primary endpoint for symptoms, were not statistically 
significant; however, the differences in the mean ocular 
discomfort scores for DP 7.5 versus placebo at several 
discrete time points during the visit 5 CAE exposure were 
statistically significant (PP-WE, Figure 5). In order to 
determine if the patients reporting lower ocular discomfort 
scores during the visit 5 CAE experienced improvements 
in any relevant dry eye signs, two subgroups of patients 
Placebo 10.5 mA-
min at 3.5 mA
N = 25
Patients randomized
N = 105
(ITT population)
DP 7.5 mA-min
at 2.5 mA
N = 41
DP 10.5 mA-min
at 3.5 mA
N = 37
Completed
N = 36
(PP = 35)
Discontinued
N = 5
Patients receiving
ocular iontophoresis
N = 103
(Safety population)
Patients screened
N = 228
Screen failures
N = 123
Inclusion criteria (108)
Exclusion criteria (15)
Completed
N = 32
(PP = 29)
Discontinued
N = 6
Completed
N = 21
(PP = 19)
Discontinued 
N = 5
Figure 3 Patient disposition. The flow chart depicts the distribution of patients throughout the study as well as inclusion/exclusion numbers, study populations, and 
treatment arms.
Abbreviations: DP, dexamethasone phosphate; iTT, intention to treat; PP, per protocol.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Table 2 Secondary endpoints: statistically significant results compared with placebo shown in bold (p <0.05).
Endpoint Analysis population Time point DP 7.5 DP 10.5 Placebo
Lissamine green staining 
(superior region)
PP-We Visit 5: change pre 
to post-CAe
Mean (sD) 1.60 (0.881) 1.78 (0.841) 2.11 (0.614)
P value1 0.0173 0.1242 –
P value2 0.0385 0.1965 –
TFBUT PP-We Visit 5, pre-CAe Mean (sD) 2.25 (0.854) 2.32 (1.193) 1.82 (0.571)
P value1 0.0339 0.0599 –
Visit 5, post-CAe Mean (sD) 2.04 (0.750) 2.09 (0.820) 1.68 (0.528)
P value1 0.0488 0.0403 –
Visit 7 Mean (sD) 2.73 (1.314) 2.39 (1.314) 1.95 (1.119)
P value1 0.0417 0.2198 –
OPi PP-We Visit 5, post-CAe n (%) $1 
n (%) ,1
19 (54.3%) 
16 (45.7%)
11 (37.9%) 
18 (62.1%)
5 (26.3%) 
14 (73.7%)
P value3 0.0482 0.4038 –
Ocular discomfort PP-We Visit 4 Mean (sD) 1.29 (0.957) 1.34 (1.261) 1.79 (0.787)
P value1 0.0437 0.1396 –
P value2 0.0320 0.0971 –
Visit 6 Mean (sD) 1.03 (0.985) 1.24 (1.091) 1.84 (0.898)
P value1 0.0038 0.0436 –
P value2 0.0032 0.0360 –
Visual analog scale (VAs) 
(ocular discomfort)
PP Visit 5, pre-CAe Mean (sD) 1.86 (0.772) 1.66 (0.936) 2.16 (0.688)
P value1 0.1498 0.0377 –
P value2 0.1746 0.0406 –
Notes: 1Two-sample t-test; 2Wilcoxon rank-sum test; 3Chi square test; All P values calculated relative to placebo.
Abbreviations: Aee, all eligible eyes; CAe, Controlled Adverse environment; ODO, observed data only; PP, per protocol; We, worst eye.
were evaluated: those demonstrating ocular discomfort 
scores of ,3 and those demonstrating ocular discomfort 
scores ,4 at all time points between 50 and 90 minutes 
during visit 5 CAE exposure. For patients in the subgroup 
scoring ,4 at all time points between 50 and 90 min-
utes during visit 5 CAE exposure, the visit 6 and 7 data 
demonstrated significantly longer mean TFBUTs for both 
active treatment groups compared with the placebo group   
(Table 3).
The ocular discomfort scores at visits 4 and 6 decrea  sed 
by about 1 unit on a scale of 0 to 4 and were statistically 
significant in the DP 7.5 treatment group versus placebo 
(P = 0.032 and P = 0.0032, respectively, Wilcoxon).
−0.6
*
−0.4
*P = 0.0377 Wilcoxon rank-sum
test versus placebo
C
o
r
n
e
a
l
 
s
t
a
i
n
i
n
g
 
s
c
o
r
e
 
(
0
 
t
o
 
4
 
s
c
a
l
e
)
v
i
s
i
t
 
1
 
m
i
n
u
s
 
v
i
s
i
t
 
7
 
(
m
e
a
n
 
+
/
−
 
9
5
%
 
C
l
)
−0.2
0.0
0.2
0.4
0.6
DP 7.5
DP 10.5
Placebo
Figure 4 Corneal staining is decreased by iontophoretic dexamethasone phosphate. 
The mean change in corneal fluorescein staining (inferior region) between visit 1 
(baseline) to visit 7 for each treatment group. Over this time frame, the DP 7.5 
treatment group showed a statistically significant decrease in staining compared with 
the placebo treatment group.
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Figure 5 Mean ocular discomfort scores during CAe exposure at visit 5. The plot 
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safety
Over the course of the study, 90 (87%) of the 103 patients 
in the safety population experienced at least 1 AE,   including 
37 patients in the DP 7.5 treatment group, 34 patients in 
the DP 10.5 treatment group, and 19 patients in the placebo 
group. Ocular AE data are summarized in Table 4. Of the 254 
treatment-emergent AEs [(TEAEs) AEs arising after patients 
received first treatment], 199 (78%) were ocular: 77 in the 
DP 7.5 treatment group, 82 in the DP 10.5 treatment group, 
and 40 in the placebo group. The most commonly reported 
ocular TEAEs were hyperemia and keratitis. No adverse 
effects on visual acuity were observed. Ten patients (9.7%) 
were withdrawn from the study due to AEs; of these, 3 were 
in the placebo treatment group (12%), 4 were in the DP 7.5 
treatment group (9.8%), and 3 were in the DP 10.5 treatment 
group (8.1%). The majority of all treatment-related ocular 
AEs resolved without sequelae within 24 hours. No severe 
AEs were observed.
Discussion
Currently, eyedrops are the main treatment regimen for dry 
eye patients. In this exploratory study, iontophoretically 
delivered dexamethasone phosphate (EGP-437) demon-
strated significant improvements in a variety of signs and 
symptoms of dry eye relative to placebo. Despite missing 
the primary endpoints at visit 5 in the ITT population, statis-
tically significant improvements were demonstrated in each 
of the 4 testing scenarios (treatment, prevention, recovery, 
and “environmental”) for the PP population.
Table 3 TFBUT in ocular discomfort subgroups. Values in bold 
are statistically significant (p , 0.05)
DP 7.5 DP 10.5 Placebo
Subgroup scoring , 3 n = 9 n = 5 n = 2
Visit 6 Mean (SD) 1.99 (0.715) 2.13 (1.314) 1.33 (0.113)
Range (1.4–3.7) (1.1–4.4) (1.3–1.4)
P value 0.0281 0.2484 –
Visit 7 Mean (SD) 2.79 (2.284) 2.39 (0.457) 1.26 (0.233)
Range (1.3–8.5) (1.6–2.8) (1.1–1.4)
P value 0.0822 0.0123 –
Subgroup scoring , 4 n = 20 n = 16 n = 8
Visit 6 Mean (SD) 2.65 (1.981) 2.42 (1.275) 1.44 (0.257)
Range (1.1–9.2) (1.1–5.2) (1.1–1.8)
P value 0.0144 0.0088 –
Visit 7 Mean (SD) 2.60 (1.693) 2.76 (1.553) 1.68 (0.623)
Range (1.0–8.5) (1.2–6.6) (0.9–2.6)
P value 0.0437 0.0239 –
Abbreviations: DP, dexamethasone phosphate; TFBUT, tear film break-up time.
Table 4 subject-reported ocular TeAes. The totals for each group, along with the number of subjects with multiple Aes, are in bold 
for emphasis.
DP 7.5 (N = 41) DP 10.5 (N = 37) Placebo  (N = 25)
Total number of ocular AEs 77 82 40
Subjects with ≥1 ocular AE1 36 (87.8%) 31 (83.8%) 16 (64.0%)
eye disorders1 27 (65.9%) 27 (73.0%) 15 (60.0%)
  Ocular hyperemia 16, 3 (39.0%) 18, 2 (48.6%) 11, 1 (44.0%)
  Keratitis 6, 3 (14.6%) 6, 4 (16.2%) 1, 0 (4.0%)
  Ocular discomfort 4, 2 (9.8%) 6, 1 (16.2%) 2, 0 (8.0%)
  Conjunctival edema 4, 0 (9.8%) 3, 1 (8.1%) 2, 0 (8.0%)
  Vision blurred 4, 0 (9.8%) 2, 0 (5.4%) 1, 0 (4.0%)
  eye irritation 1, 0 (2.4%) 3, 1 (8.1%) 2, 0 (8.0%)
  eye pain 3, 2 (7.3%) 1, 1 (2.7%) 2, 0 (8.0%)
  Foreign body sensation in eyes 2, 1 (4.9%) 3, 1 (8.1%) 1, 0 (4.0%)
  Photopsia 2, 0 (4.9%) 2, 0 (5.4%) 1, 0 (4.0%)
  Photophobia 0 3, 1 (8.1%) 1, 0 (4.0%)
  Punctate keratitis 2, 0 (4.9%) 1, 0 (2.7%) 0
  Dry eye 1, 0 (2.4%) 1, 0 (2.7%) 0
  eye pruritis 1, 1 (2.4%) 0 1, 1 (4.0%)
  Abnormal sensation in eye 1, 1 (2.4%) 0 0
  Corneal deposits 0 1, 0 (2.7%) 0
  erythema of eyelid 1, 0 (2.4%) 0 0
  eyelid margin crusting 0 0 1, 0 (4.0%)
  Lacrimation increased 0 1, 1 (2.7%) 0
  Lenticular opacities 1, 0 (2.4%) 0 0
  Vitreous detachment 0 1, 0 (2.7%) 0
  Vitreous floaters 1, 0 (2.4%) 0 0
Notes:  1Table entries [n, m (%)] represent the total number (n) of subjects reporting 1 or more treatment-emergent ocular AEs. The number of those classified as 
moderate (m), and the corresponding percentage of total subjects in that treatment group.
Abbreviations: Ae, adverse event; TeAe, treatment-emergent adverse event; DP, dexamethasone phosphate.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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The decreased ocular discomfort reported during the visit 
5 CAE between the 60- and 90-minute timepoints (within 
2 hours of the second treatment), observed 24 hours (recovery) 
following CAE exposure at visits 4 (treatment) and 6 (pre-
vention), pre- to post-CAE comparison of   lissamine green 
corneal staining at visit 5   (prevention), TFBUT   post-CAE at 
visit 5 (prevention), and OPI post-CAE at visits 5 (preven-
tion) and 6 (prevention and treatment) suggest a rapid onset 
of action for iontophoresis-delivered EGP-437.
Fluorescein staining in the inferior region (Ora scale) 
is recognized as an important sign of dry eye disease, 
because this area represents a region specifically vulner-
able to exacerbation by stress conditions,25 including 
those presented in the CAE model. The DP 7.5 treatment 
improved the inferior region (Ora scale) fluorescein stain-
ing observed from visit 1 baseline to visit 7 by 0.51 units 
relative to placebo (“environmental”) demonstrating that 
the 2 iontophoresis treatments over the 3 weeks may aid 
healing in this region. These findings, in conjunction 
with the increased TFBUT measured at visit 5 pre-CAE   
(a week after the first iontophoresis treatment), and visit 7 
(a week after the second iontophoresis treatment), as well 
as the ocular discomfort score at visit 5 pre-CAE, sug-
gest that iontophoresis-delivered EGP-437 may provide 
beneficial effects for dry eye patients without the need for 
daily dosing.
Since multiple statistically significant observations were 
made across a variety of visits and endpoints, it is likely that 
the effects are treatment-related. Based on all endpoints ana-
lyzed, it appears that the lower dose, DP 7.5 is more effective 
than the higher dose, DP 10.5. One possible explanation for 
the lower efficacy of the higher dose may be a difference 
in ocular drug distribution. It is   possible that the higher 
current dose may drive the drug more deeply within the 
globe rather than delivering more drug to the ocular surface 
and anterior segment, as revealed in rabbit biodistribution 
studies.23 In response to this observation, future research 
will likely focus on treatment effects of dexamethasone 
phosphate 40 mg/mL at lower iontophoretic doses.
Although a majority of patients experienced some dis-
comfort related to the iontophoresis procedures, most AEs 
were mild and there were no severe events. Most events 
were associated with the mild discomfort of having the 
device applied to the eye or with the sensations, for example, 
tingling in the eye during treatment. More AEs occurred at 
visit 3 than at visit 5. This may be attributed to the fact that 
patients at visit 3 received treatment post-CAE exposure, 
at the time in the study when their eyes were most dry and 
irritated versus visit 5 when patients received treatment pre-
CAE. Previous work with iontophoresis has shown similar 
treatment-related hyperemia that diminished after multiple 
iontophoretic applications.20,32
The AEs of corneal staining in the trial described 
herein may have been a result of enhanced ocular surface 
  vulnerability related to the CAE and/or to the external 
environment while patients received treatment with their 
eyes open for 3 minutes. Additional research is required 
to confirm this. Furthermore, electroencephalogram, 
electrocardiogram, electroretinogram, and IOP safety data 
obtained in an earlier healthy volunteer study utilizing 
this delivery system demonstrated no substantial risk of 
abnormalities.33
In another clinical study (n = 40), following a single ion-
tophoretic treatment with EGP-437, mean IOP remained rela-
tively stable and within normal range in patients whose IOPs 
were monitored weekly over 28 days after treatment.34
If the drug exposure profiles in humans are similar to 
those measured in animals,23 then iontophoretic treatment 
with dexamethasone phosphate may convey similar safety 
advantages to those seen with therapeutic approaches using 
tapered or “pulse” systemic steroids relative to chronic 
steroid dosing.
EGP-437 treatment via the EyeGate® II system dem-
onstrated positive effects on patients’ dry eye signs and 
symptoms in the PP population and may represent a potential 
alternative dosing approach for corticosteroids in dry eye 
patients. However, the specific duration of action and dos-
ing rationale still need to be established through additional 
studies. The study sample included a broad range of dry eye 
patients, and was not limited to those with low tear produc-
tion; therefore, EGP-437 has the potential to be efficacious 
in a larger proportion of patients than Restasis®. Further 
clinical work is required.
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